Janux Therapeutics Stock Forecast
NASDAQ: JANXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 18.50 0.00%
JANX analyst consensus
Consensus (18 analysts)
strong_buy
Avg. price target
$36.24+95.89%
- Strong buy 2
- Buy 14
- Hold 1
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 18 Wall Street analysts covering Janux Therapeutics (2026-10-08), 16 rate the stock a buy or strong buy, 1 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $36.24, with a high estimate of $75.00 and a low estimate of $14.00. The average target implies upside of 95.9% from the current price of $18.50.
The spread between the highest and lowest targets is 435.7%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for JANX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 11% |
| Buy | 14 | 78% |
| Hold | 1 | 6% |
| Sell | 0 | 0% |
| Strong sell | 1 | 6% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $14.00 | -24.32% |
| Average target | $36.24 | +95.89% |
| High target | $75.00 | +305.41% |